Clinical and preclinical activity of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk of hematologic malignancies, against blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Arthur E. Frankel
Research Funding - Stemline Therapeutics
Jung Hee Woo
No relevant relationships to disclose
Jeremy Preston Mauldin
No relevant relationships to disclose
Hetty Eileen Carraway
No relevant relationships to disclose
Olga Frankfurt
No relevant relationships to disclose
Stephen J. Forman
No relevant relationships to disclose
Christopher Brooks
Employment or Leadership Position - Stemline Therapeutics
Ivan Bergstein
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics (B)
Thomas Cirrito
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics (B)
Eric K. Rowinsky
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics (B)